Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Research Center of Pediatric Infectious Diseases, Institute of Immunology and Infectious Diseases, Iran University of Medical Sciences, Tehran, Iran.
Eur J Clin Microbiol Infect Dis. 2020 Dec;39(12):2257-2267. doi: 10.1007/s10096-020-03963-z. Epub 2020 Jun 29.
Streptococcus pneumoniae is associated with high morbidity and mortality in the world. Commercially licensed and available pneumococcal conjugate vaccines (PCVs) contain 10 (PCV10) and 13 (PCV13) pneumococcal serotypes. The most common serotypes of S. pneumoniae causing clinical diseases and carriers of S. pneumoniae in Iran are not yet known. Reviewing and reporting trends in the distribution of pneumococcal serotypes in Iran will be useful for policy-making as PCV is being introduced into Iran's routine immunization program. Here, we report a systematic literature review of studies regarding S. pneumoniae serotype distribution in clinical and carrier patients in Iran. MEDLINE (via PubMed), Scopus, Embase, Ovid, Google Scholar, Web of Science, and the Iranian Database were used to identify relevant papers published from 1 January 2000 to 21 August 2019. The search returned 8 relevant articles. Among serotypes causing invasive pneumococcal diseases (IPD), serotype 23F (16.4%) was the most circulating serotype followed by 19F (15.2%), 19A (11.3%), 6A/B (9.2%), 9 V (5.8%), and 11A (5.14%). In carrier patients, the most common serotypes were, in rank order, 6A/B (10%), 19F (9%), 14(6.2%), 17F (4.8%), and 20(4.5%). Vaccine coverage among IPD patients would be 67.1% for PCV10-TT and 73.8% for PCV13. The present review demonstrates that the serotypes which were most responsible for disease in Iran are included in PCV10-TT and PCV13. However, sentinel surveillance must be continued in representative parts of the country to assess changing trends in the distribution of pneumococcal serotypes and their implications for vaccine selection and rollout in Iran.
肺炎链球菌在全球范围内与高发病率和死亡率相关。已获得商业许可并可应用的肺炎球菌结合疫苗(PCV)包含 10 种(PCV10)和 13 种(PCV13)肺炎球菌血清型。在伊朗,引起临床疾病的最常见肺炎链球菌血清型以及肺炎链球菌携带者尚未可知。在肺炎球菌结合疫苗被引入伊朗常规免疫规划的情况下,对伊朗肺炎球菌血清型分布趋势进行综述和报告将有助于制定政策。在此,我们对伊朗临床和携带者患者肺炎链球菌血清型分布的相关研究进行了系统的文献综述。通过 MEDLINE(通过 PubMed)、Scopus、Embase、Ovid、Google Scholar、Web of Science 和伊朗数据库,检索了 2000 年 1 月 1 日至 2019 年 8 月 21 日发表的相关文献。检索共返回 8 篇相关文章。在引起侵袭性肺炎球菌病(IPD)的血清型中,血清型 23F(16.4%)是最常见的流行血清型,其次是 19F(15.2%)、19A(11.3%)、6A/B(9.2%)、9V(5.8%)和 11A(5.14%)。在携带者患者中,最常见的血清型依次为 6A/B(10%)、19F(9%)、14(6.2%)、17F(4.8%)和 20(4.5%)。对于 IPD 患者,PCV10-TT 的疫苗覆盖率为 67.1%,PCV13 的疫苗覆盖率为 73.8%。本综述表明,伊朗引起疾病的主要血清型均包含在 PCV10-TT 和 PCV13 中。然而,必须在该国具有代表性的地区继续进行哨点监测,以评估肺炎球菌血清型分布的变化趋势及其对伊朗疫苗选择和推广的影响。